Background -Use of the second-generation cryoballoon (CB) for pulmonary vein isolation
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Introduction
The cryoballoon (CB, Artic Front Advance, Medtronic, Inc., Minneapolis, MN, USA) has gained increasing acceptance as an effective ablation tool for pulmonary vein isolation (PVI). While the first-generation CB demonstrated moderate long-term clinical efficacy combined with an acceptable safety profile, 1-3 the second-generation CB has been optimized for better performance. Despite an identical outer shape, modifications to the refrigerant injection system allow for improved cooling of the distal balloon hemisphere. Initial acute and midterm clinical results have been published reporting an improvement in efficacy if compared to the firstgeneration CB. 4, 5 Furthermore, the rate of phrenic nerve (PN) palsy 6,7 and esophageal thermal injury 8, 9 has been described. However, 1-year clinical outcome following PVI using the secondgeneration 28mm CB-has not yet been reported.
Methods

Inclusion and exclusion criteria
Consecutive patients with symptomatic, drug-refractory paroxysmal AF or short-standing -based PVI.
Exclusion criteria were prior left atrial (LA) ablation, LA diameter >60 mm, severe valvular heart disease or contraindications to postinterventional oral anticoagulation. Transesophageal echocardiography was performed prior to PVI to assess the LA diameter and to rule out intracardiac thrombi. No additional preprocedural imaging was performed.
The study was approved by our institutional review committee. All patients gave written informed consent.
Intraprocedural management
In brief, the procedure was performed under deep sedation using midazolam, fentanyl, and omp pared to the firs rs s st-t-t-tand d es esop opha ha h h ge geal al th th th the e er erm a a as be be been en en e d d d des es es e c crib ib ib bed e e . However, 1-year clin n n nic ic ic ical a outcome fo o ollow w w win i i g PVI using the se 2 2 28 2 m m mm m CB-ha as not t t y yet be be be een re repo o or rted d.
an a d d ex e cl c us s usio io i n cr c it it it iter e ia ia ia i
propofol. Prior to transseptal puncture (TP), two diagnostic catheters were introduced via the right femoral vein and positioned within the coronary sinus and along the His-bundle. 
PVI using the second-generation 28mm CB
The 28mm CB was advanced into the LA via the 12F steerable sheath using a spiral mapping catheter (15 mm or 20 mm diameter; Achieve TM , Medtronic, Inc., Minneapolis, MN, USA) as a guidewire. The CB was inflated proximal to the PV ostium followed by gentle push aiming for complete sealing at the antral aspect of the PV. Contrast medium injected through the central lumen of the CB was used to verify complete occlusion of the PV ostium. This was followed by a freeze cycle of 240 seconds. After successful PVI one additional bonus freeze of 240ms duration was applied.
The procedural endpoint was defined as persistent PVI verified by spiral mapping catheter recordings 30 min after the last energy application.
Phrenic nerve pacing
During cryoenergy application along the septal PVs, continuous pacing of the PN was performed 
Postprocedural Care
Following ablation, all patients underwent transthoracic echocardiography to rule out pericardial effusion. All patients were treated with proton-pump inhibitors twice daily for 6 weeks. Low molecular-weight heparin was administered in patients on vitamin K antagonists and an INR <2.0 until a therapeutic INR of 2-3 was achieved. Novel oral anticoagulants were reinitiated 6 hours post ablation. Anticoagulation was continued for at least 3 months and continued thereafter based on the individual CHA 2 DS 2 -VASC score. Previously ineffective antiarrhythmic drugs were continued for 3 months.
Repeat procedures
In patients admitted for a repeat procedure due to AF recurrence, venous access and TP were performed as previously described. The presence or absence of electrical activity inside the PVs was assessed using a spiral mapping catheter. An electroanatomical LA map (Carto TM , Biosense
Webster) was generated and the PV ostia were tagged. Identified gaps within the previously performed ablation lines were closed by irrigated RF ablation using a 3.5 mm irrigated-tip catheter (Biosense Webster, Navi-Star TM , Thermo-Cool TM ). The procedural endpoint was complete electrical PVI.
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Follow-up
Following a blanking period of 3 months, patients completed outpatient clinic visits at 3, 6 and 12 months including 24h-Holter ECGs. In addition, regular telephonic interviews were performed. Additional outpatient clinic visits were immediately initiated in case of symptoms suggestive of recurrent arrhythmia.
Endpoints
The primary endpoint was AF recurrence, defined as a documented episode of AF >30sec, either symptomatic or asymptomatic, on Holter-ECG and/or 12-lead ECG. Secondary endpoints were defined as procedure related complications such as PN palsy, cerebral embolism or atrioesophageal fistula.
Statistical analysis
Continuous data are shown as mean and standard deviation. Survival curves were generated with the Kaplan-Meier technique. All p-values are two-sided and a p<0.05 was considered significant. patients, respectively (table 1) . Mean procedure duration was 140±28 min including a waiting period of 30 min. Mean fluoroscopy time was 25±8 min.
Results
Patient characteristics
Acute ablation results
In
Complications
As the only complication, PN palsy occurred in 1/50 (2%) patients during cryoablation along the RSPV. The PN palsy was persistent throughout the hospital stay and during fluoroscopic reevaluation at 3 and 6 months post ablation. However, PN palsy completely resolved 10 months post ablation.
No pericardial effusion, pericardial tamponade, symptomatic PV stenosis, cerebral embolism, or atrioesophageal fistula occurred in any of the remaining patients.
Clinical follow-up
Clinical long-term FU was obtained in 49/50 (98%) patients, while 1/50 (2%) patients was lost to 
Repeat procedures
A total of 8/10 (80%) patients suffering from arrhythmia recurrence underwent a second ablation procedure using RF 207±119 days after the index procedure. LA to PV reconduction in at least one right-sided PV was found in 7/8 (88%) patients and in at least one left-sided PV in 6/8 (75%) patients, respectively. In 1/8 (13%) patients with PAF, 2 focal ATs were mapped and ablated within the LA in addition to re-isolation of the PVs. In a second patient with PAF an additional anterior line, a roofline and a posterior line were deployed within the LA due a macro-reentrant AT.
For the second procedure, the mean procedure time was 160±50 min using a mean fluoroscopy time of 19±10 min.
Discussion
This is the first study to report one-year FU outcome following PVI using the second-generation 28mm CB. The current study found that (1) the 1-year clinical success rate was 80% (81% for paroxysmal AF, 77% for short-term persistent AF) and thus superior to reported long-term FU using the first generation CB; (2) all patients with tachyarrhythmia recurrence had at least one PV demonstrating LA to PV reconduction as a potential source for arrhythmia recurrence, and (3) the peri-and postinterventional complication rate was low. The first-generation CB has demonstrated acute and long-term clinical results comparable to RF ablation with a similar safety profile. [1] [2] [3] 11, 12 A freeze cycle of 300 sec in duration resulting in acute PVI was typically followed by a bonus freeze of the same duration. Applying a second
bonus freeze failed to demonstrate additional benefit and was associated with an increase in complications. 13 Via a spiral mapping catheter (Achieve) introduced through the central lumen of the catheter PV signals could be recorded allowing for live verification of PVI in approximately 49% of targeted PVs.
4
By contrast, the second-generation CB incorporates a modified refrigerant injection system providing homogeneous cooling of the complete distal balloon hemisphere resulting in extensive ice formation on the balloon surface. 10 Initial studies demonstrated an improvement in procedural efficacy compared to the first-generation balloon with an 84% acute isolation rate during the first freeze cycle. 4 Furthermore, the rate of live registration of electrical PVI via the spiral mapping catheter increased from 49% to 76% when comparing both CB generations. 4 In turn, an increase in acute efficacy has led to a higher rate of injury to adjacent non-cardiac anatomical structures such as the esophagus or PN. The incidence of esophageal thermal injury following PVI using the 28mm second-generation CB ranges between 12% to 19%. 8, 9 Based on these results, safety cut-offs for the intra luminal esophageal temperature were developed to reduce the risk of esophageal thermal injury. 8, 9 The incidence of PN palsy during secondgeneration CB based PVI was reported as high as 19.5%. 6 At our center the rate is 3.5% 7 and thus comparable to the first-generation CB. 3 In our electrophysiology laboratories only the 28mm CB is used because of two reasons:
First, our rate of acute PVI using only the 28mm CB is 99%. Second, the 28mm CB is usually bigger than a normal-sized PV. This leads to an ablation lesion covering a substantial portion of crease in ac te efficac has led to a higher rate of inj r to adjacent non cardiac ce fo fo form rm rmat at atio io ion on on on the balloon surface. 10 In nit it itia ia i l studies de e emons ns nstrated an improveme e e eff f ficacy comp pa ared d d t t to th h he e e firs st t t-g g gen nerat at tion n b ball l loo oo oon n n w wit th h an 84 84% % % a a acute e e is is iso ola atio o on n ra first t t fr fr free ee eeze cycl l le. Only 6-month clinical outcome data using the second-generation 28mm CB has been reported to date. 4 Applying a single 180 sec freeze cycle 82% of patients remained in sinus rhythm. 4 In the current study freeze cycle duration was 240 sec and, following successful PVI, a bonus freeze of the same duration was applied. Using this protocol, the 1-year clinical success rate was 80%. Compared to published results from our center using the first-generation 28mm CB in patients with PAF applying a 300 sec freeze cycle, the 1-year success rate improved from 52% to 80%.
13
The encouraging results reported in the present study raise the question whether a bonus freeze cycle after successful PVI is actually necessary. While 6-month results following a single freeze application are encouraging, long-term outcome data will have to provide more data to support a "single-shot" strategy. In view of the high rate of live verification of successful PVI using the Achieve catheter, future studies may focus on time-to-effect, that is, adjusting freeze cycle duration to the individual patient depending on the time to isolation. 4 A reduction in the number or duration of individual freeze cycles per PV may also contribute to shorter procedure and fluoroscopy times while further decreasing the risk for adverse events.
In the current study all patients with arrhythmia recurrence who underwent a second, RF ablation procedure demonstrated electrical LA-to-PV reconduction into at least 1 PV. The precise evaluation of the quantity and location of reconduction gaps needs further evaluation and will be the focus of upcoming studies.
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Limitations
The present study represents the experience of a single-center. No comparison group was included. However, results are compared with the outcome of a patient cohort from our center previously published using the first generation 28mm CB and a similar ablation protocol (one bonus freeze cycle, 300 sec freeze duration).
11,13
Conclusions
Use of the second-generation 28mm CB for PVI results in an 80% 1-year success rate. Future studies will need to evaluate whether forgoing a bonus freeze results in similar encouraging longterm outcome. cryoballoon during a follow-up period of 440±39 days including a 3-month blanking period.
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